Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
February 28, 2025 16:04 ET
|
Longeveron
Longeveron announces 2024 financial results and provides business update. Pivotal Phase 2b clinical trial achieves 90% enrollment.
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer
February 26, 2025 07:00 ET
|
Wugen
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
February 20, 2025 12:00 ET
|
Neurona Therapeutics
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
Le Centre C3i, une compagnie canadienne, reçoit l'approbation de l’EMA pour fabriquer des produits de thérapie cellulaire pour le marché européen
February 19, 2025 09:00 ET
|
Centre C3i Inc.
C3i reçoit une certification de conformité aux Bonnes pratiques de fabrications (BPF) par l'Agence européenne des medicaments (EMA)
C3i Center, a Canadian company, receives approval from the EMA to manufacture cell therapy products for the European market
February 19, 2025 09:00 ET
|
Centre C3i Inc.
C3i receives a certificate of Good Manufacturing Practice (GMP) compliance by the European Medicines Agency (EMA).
Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
February 18, 2025 09:25 ET
|
Longeveron
WHO approved generic name laromestrocel for stem cell therapy Lomecel-B, being developed as potential treatment for Alzheimer's disease and HLHS.
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
February 14, 2025 16:03 ET
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be...
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
February 14, 2025 09:05 ET
|
Longeveron
Longeveron to present at the Emerging Growth Virtual Conference taking place February 18-19, 2025.
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
February 13, 2025 08:00 ET
|
Vor Biopharma
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT)...
Cell Therapy Human Raw Materials Market Research Report 2025-2030: Revenues Set to Double, Reaching $5.43 Billion by 2030
February 11, 2025 09:19 ET
|
Research and Markets
Dublin, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The "Cell Therapy Human Raw Materials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...